Aryeh Fischer1,2, Amanda M Kong1,2, Jeffrey J Swigris1,2, Ashley L Cole1,2, Karina Raimundo3,4. 1. From the University of Colorado School of Medicine, Denver, Colorado; Truven Health Analytics, an IBM Company, Cambridge, Massachusetts; National Jewish Health, Denver, Colorado; Genentech Inc., South San Francisco, California, USA. 2. A. Fischer, MD, University of Colorado School of Medicine; A.M. Kong, MPH, Truven Health Analytics, an IBM Company; J.J. Swigris, DO, MS, National Jewish Health; A.L. Cole, MPH, Truven Health Analytics; K. Raimundo, MS, Genentech Inc. 3. From the University of Colorado School of Medicine, Denver, Colorado; Truven Health Analytics, an IBM Company, Cambridge, Massachusetts; National Jewish Health, Denver, Colorado; Genentech Inc., South San Francisco, California, USA. raimundo.karina@gene.com. 4. A. Fischer, MD, University of Colorado School of Medicine; A.M. Kong, MPH, Truven Health Analytics, an IBM Company; J.J. Swigris, DO, MS, National Jewish Health; A.L. Cole, MPH, Truven Health Analytics; K. Raimundo, MS, Genentech Inc. raimundo.karina@gene.com.
Abstract
OBJECTIVE: Patients with systemic sclerosis (SSc) often develop interstitial lung disease (ILD) and/or pulmonary arterial hypertension (PAH). The effect of ILD and PAH on healthcare costs among patients with SSc is not well described. The objective of this analysis was to describe healthcare costs in patients with newly diagnosed SSc and SSc patients newly diagnosed with ILD and/or PAH in the United States. METHODS: This retrospective cohort analysis was conducted in the Truven Health MarketScan Commercial and Medicare Supplemental healthcare claims databases from 2003 to 2014. Based on International Classification of Diseases-9-Clinical Modification diagnosis codes on medical claims, patients were classified into 3 groups: incident SSc, SSc with incident ILD (SSc-ILD), and SSc with incident PAH (SSc-PAH). Patients were required to have continuous enrollment for 5 years to measure all-cause healthcare costs. Costs (adjusted to US$) were reported overall and by service type and year following diagnosis. Because of the overlap between groups, statistical comparisons were not conducted. RESULTS: There were 1957 patients with incident SSc, 219 with incident SSc-ILD, and 108 patients with incident SSc-PAH. Average (mean ± SD) all-cause healthcare costs over followup were higher for patients with incident SSc-ILD ($191,107 ± $322,193) or patients with incident SSc-PAH ($254,425 ± $240,497), compared to patients with incident SSc ($101,839 ± $167,155). Average annual costs over the 5-year period ranged from $18,513 to $23,268 for patients with incident SSc, from $31,285 to $55,446 for patients with incident SSc-ILD, and from $44,454 to $63,320 for patients with incident SSc-PAH. Costs tended to be the highest in the fifth year of followup. CONCLUSION: Among patients with SSc, ILD and PAH can result in substantial increases in healthcare costs.
OBJECTIVE:Patients with systemic sclerosis (SSc) often develop interstitial lung disease (ILD) and/or pulmonary arterial hypertension (PAH). The effect of ILD and PAH on healthcare costs among patients with SSc is not well described. The objective of this analysis was to describe healthcare costs in patients with newly diagnosed SSc and SSc patients newly diagnosed with ILD and/or PAH in the United States. METHODS: This retrospective cohort analysis was conducted in the Truven Health MarketScan Commercial and Medicare Supplemental healthcare claims databases from 2003 to 2014. Based on International Classification of Diseases-9-Clinical Modification diagnosis codes on medical claims, patients were classified into 3 groups: incident SSc, SSc with incident ILD (SSc-ILD), and SSc with incident PAH (SSc-PAH). Patients were required to have continuous enrollment for 5 years to measure all-cause healthcare costs. Costs (adjusted to US$) were reported overall and by service type and year following diagnosis. Because of the overlap between groups, statistical comparisons were not conducted. RESULTS: There were 1957 patients with incident SSc, 219 with incident SSc-ILD, and 108 patients with incident SSc-PAH. Average (mean ± SD) all-cause healthcare costs over followup were higher for patients with incident SSc-ILD ($191,107 ± $322,193) or patients with incident SSc-PAH ($254,425 ± $240,497), compared to patients with incident SSc ($101,839 ± $167,155). Average annual costs over the 5-year period ranged from $18,513 to $23,268 for patients with incident SSc, from $31,285 to $55,446 for patients with incident SSc-ILD, and from $44,454 to $63,320 for patients with incident SSc-PAH. Costs tended to be the highest in the fifth year of followup. CONCLUSION: Among patients with SSc, ILD and PAH can result in substantial increases in healthcare costs.
Authors: Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener Journal: Chest Date: 2018-11-22 Impact factor: 9.410
Authors: Janelle Vu Pugashetti; Aleksander Kitich; Shehabaldin Alqalyoobi; Anne-Catherine Maynard-Paquette; David Pritchard; Julia Graham; Noelle Boctor; Andrea Kulinich; Elyse Lafond; Elena Foster; Cesar Mendez; Saad Choudhry; Jean Chalaoui; Julie Morisset; Michael Kadoch; Justin M Oldham Journal: Chest Date: 2020-03-14 Impact factor: 9.410
Authors: Stephen C Mathai; Anna Ryan Hemnes; Scott Manaker; Rebekah H Anguiano; Bonnie B Dean; Vishal Saundankar; Peter Classi; Andrew C Nelsen; Kathryn Gordon; Corey E Ventetuolo Journal: Ann Am Thorac Soc Date: 2019-07
Authors: David Pritchard; Ayodeji Adegunsoye; Elyse Lafond; Janelle Vu Pugashetti; Ryan DiGeronimo; Noelle Boctor; Nandini Sarma; Isabella Pan; Mary Strek; Michael Kadoch; Jonathan H Chung; Justin M Oldham Journal: Respir Res Date: 2019-11-12
Authors: Michael Kreuter; Francesco Del Galdo; Corinna Miede; Dinesh Khanna; Wim A Wuyts; Laura K Hummers; Margarida Alves; Nils Schoof; Christian Stock; Yannick Allanore Journal: Arthritis Res Ther Date: 2022-01-10 Impact factor: 5.156
Authors: Gustavo A Heresi; Bonnie B Dean; Howard Castillo; Henry F Lee; Peter Classi; Dana Stafkey-Mailey; Alexander Kantorovich; Kellie Morland; Margaret R Sketch; Benjamin S Wu; Christopher S King Journal: Lung Date: 2022-03-29 Impact factor: 2.584